Yeminia Valle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4760451/publications.pdf

Version: 2024-02-01

933447 940533 31 302 10 16 citations h-index g-index papers 31 31 31 573 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatology International, 2012, 32, 2307-2311.	3.0	33
2	The +49A>G CTLA-4 polymorphism is associated with rheumatoid arthritis in Mexican population. Clinica Chimica Acta, 2010, 411, 725-728.	1.1	32
3	The â^'319C/+49G/CT60G Haplotype of CTLA-4 Gene Confers Susceptibility to Rheumatoid Arthritis in Mexican Population. Cell Biochemistry and Biophysics, 2013, 67, 1217-1228.	1.8	29
4	Association of the \hat{a}^{10317} gt; C polymorphism and soluble TNF- \hat{l}_{\pm} levels with Acute Coronary Syndrome. Cytokine, 2016, 78, 37-43.	3.2	18
5	Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis. Immunobiology, 2018, 223, 135-141.	1.9	17
6	The 14 bp Del/Ins HLA-G Polymorphism Is Related with High Blood Pressure in Acute Coronary Syndrome and Type 2 Diabetes Mellitus. BioMed Research International, 2014, 2014, 1-8.	1.9	16
7	PADI4 polymorphisms and the functional haplotype are associated with increased rheumatoid arthritis susceptibility: A replication study in a Southern Mexican population. Human Immunology, 2017, 78, 553-558.	2.4	16
8	Association between the â^'794 (CATT) _{5â€''8} â€%â€% <i>MIF</i> Gene Polymorphism and Susceptib to Acute Coronary Syndrome in a Western Mexican Population. Journal of Immunology Research, 2014, 2014, 1-5.	oility 2.2	14
9	Interleukin-17A Levels Vary in Relapsing-Remitting Multiple Sclerosis Patients in Association with Their Age, Treatment and the Time of Evolution of the Disease. NeuroImmunoModulation, 2016, 23, 8-17.	1.8	13
10	Role of Toll-Interacting Protein Gene Polymorphisms in Leprosy Mexican Patients. BioMed Research International, 2013, 2013, 1-7.	1.9	10
11	Polimorfismos de los genes APOA1 y APOB y concentraciones de sus apolipoproteÃnas como biomarcadores de riesgo en el sÃndrome coronario agudo: relación con la efectividad del tratamiento hipolipemiante. Medicina ClÃnica, 2018, 151, 1-7.	0.6	10
12	The -844 G>A PAI-1 Polymorphism Is Associated with Acute Coronary Syndrome in Mexican Population. Disease Markers, 2015, 2015, 1-7.	1.3	8
13	A new PCR-RFLP assay for –1123 G>C polymorphism in the PTPN22 gene: allele and genotype frequencies in a western Mexican population. Clinical Chemistry and Laboratory Medicine, 2009, 47, 491-3.	2.3	7
14	Relationship Between C-Reactive Protein Serum Concentration and the 1846 C>T (rs1205) Polymorphism in Patients with Acute Coronary Syndrome from Western Mexico. Genetic Testing and Molecular Biomarkers, 2017, 21, 334-340.	0.7	7
15	Association of PTPN22Haplotypes ($\hat{a}^{1123G}/H1858C$) with Rheumatoid Arthritis in Western Mexican Population. International Journal of Genomics, 2017, 2017, 1-5.	1.6	7
16	ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. Endocrinologia, Diabetes Y NutriciÓn, 2019, 66, 502-511.	0.3	7
17	RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. International Journal of Molecular Sciences, 2021, 22, 7106.	4.1	7
18	Th1/Th17 Cytokine Profile is Induced by Macrophage Migration Inhibitory Factor in Peripheral Blood Mononuclear Cells from Rheumatoid Arthritis Patients. Current Molecular Medicine, 2019, 18, 679-688.	1.3	7

#	Article	IF	Citations
19	Polimorfismo â^'1123G>C en el gen PTPN22 y anticuerpos antipéptido citrulinado cÃclico en la artritis reumatoide. Medicina ClÃnica, 2017, 149, 95-100.	0.6	6
20	Association of <i><scp>CD</scp>28</i> and <i><scp>CTLA</scp>4</i> haplotypes with susceptibility to primary Sjögren′s syndrome in Mexican population. Journal of Clinical Laboratory Analysis, 2019, 33, e22620.	2.1	6
21	Population data and mutation rate of nine Y-STRs in a mestizo Mexican population from Guadalajara, Jalisco, México. Legal Medicine, 2008, 10, 319-320.	1.3	5
22	Assessment of the E-Selectinrs 5361 (561A>C) Polymorphism and Soluble Protein Concentration in Acute Coronary Syndrome: Association with Circulating Levels. Mediators of Inflammation, 2014, 2014, 1-10.	3.0	5
23	Influence of haplotypes, gene expression and soluble levels of L-selectin on the risk of acute coronary syndrome. Gene, 2017, 625, 31-41.	2.2	5
24	Genetic variants, gene expression, and soluble <scp>CD36</scp> analysis in acute coronary syndrome: Differential protein concentration between <scp>ST</scp> â€segment elevation myocardial infarction and unstable angina. Journal of Clinical Laboratory Analysis, 2022, 36, .	2.1	5
25	Plasminogen activator inhibitor-1 polymorphisms (â^'844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables. Clinical and Experimental Medicine, 2011, 11, 11-17.	3.6	4
26	Analysis of the APOB Gene and Apolipoprotein B Serum Levels in a Mexican Population with Acute Coronary Syndrome: Association with the Single Nucleotide Variants rs1469513, rs673548, rs676210, and rs1042034. Genetical Research, 2022, 2022, 1-8.	0.9	3
27	MIF mRNA Expression and Soluble Levels in Acute Coronary Syndrome. Cardiology Research and Practice, 2018, 2018, 1-6.	1.1	2
28	Analysis of Genetic Variation in CD40 and CD40L: Relationship with mRNA Relative Expression and Soluble Proteins in Acute Coronary Syndrome. Journal of Immunology Research, 2019, 2019, 1-11.	2.2	2
29	Transforming Growth Factor Beta (TFG- \hat{l}^2) Concentration Isoforms are Diminished in Acute Coronary Syndrome. Cell Biochemistry and Biophysics, 2018, 76, 433-439.	1.8	1
30	Five X-chromosome short tandem repeats in a Western Mexican population. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1388-90.	2.3	0
31	Association between the -844 G>A, HindIII C>G, and 4G/5G PAI-1 Polymorphisms and Susceptibility to Multiple Sclerosis in Western Mexican Population. Disease Markers, 2019, 2019, 1-5.	1.3	О